Background
Advanced oesophagogastric carcinoma has limited options following failure of first-or second-line chemotherapy. Regorafenib is an oral multi-kinase inhibitor of kinases involved in angiogenesis, tumor microenvironment, and oncogenesis. This study examined whether regorafenib has sufficient activity and safety for further evaluation.
Methods
International (Australia & New Zealand, Korea, Canada (NCIC CTG)) randomised phase II trial with 2:1 randomisation and stratification by: 1. Lines of prior chemotherapy for advanced disease (1 vs 2), and 2. region. Eligible patients received best supportive care plus 160 mg regorafenib or matching placebo orally on days 1-21 each 28-day cycle until disease progression or prohibitive adverse events. Primary endpoint was progression free survival in the regorafenib arm, assuming median 8 weeks in the placebo arm, aiming for 13.2 wks with regorafenib to be of interest.
Results
From November 2012 to February 2014, 152 patients were enrolled, 147 evaluable (prespecified primary-analysis population): (regorafenib, n=97: placebo, n=50); well matched for key baseline prognostic indicators: male:female (118:29); primary location: oesophagogastric junction (56), stomach (85); lines of prior therapy: 1 (63), 2 (84); ECOG 0 (62): 1 (85). Median time on treatment: 7.9 (regorafenib) v 4 (placebo) weeks. In the evaluable population, median progression-free survival was 11.1 wks (95% CI, 7.7-12.3) (regorafenib) and 3.9 wks (95% CI, 3.7-4.0) (placebo), log-rank P<0.0001, hazard ratio 0.41 (95% CI, 0.28-0.59).
Progression-free survival results were maintained for secondary analysis including all randomized patients (n=152). Regorafenib was well tolerated, with the spectrum of toxicity in keeping with previous reports.
Conclusions
Progression-free survival was clearly significantly longer with regorafenib than placebo, though progression-free survival in the placebo group was less than anticipated.
The prespecified exploratory comparisons provide compelling evidence that regorafenib has sufficient activity with acceptable tolerability in refractory advanced oesophagogastric carcinoma to warrant phase III evaluation. Mature results for overall survival will be presented at the meeting.
Clinical trial information: ANZCTR 12612000239864.
